GPR119
Glucose-dependent insulinotropic receptor
Protein Summary
Receptor for the endogenous fatty-acid ethanolamide oleoylethanolamide (OEA) and lysophosphatidylcholine (LPC). Functions as a glucose-dependent insulinotropic receptor. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Seems to act through a G(s) mediated pathway. This gene encodes a member of the rhodopsin subfamily of G-protein-coupled receptors that is expressed in the pancreas and gastrointestinal tract. The encoded protein is activated by lipid amides including lysophosphatidylcholine and oleoylethanolamide and may be involved in glucose homeostasis. This protein is a potential drug target in the treatment of type 2 diabetes.[provided by RefSeq, Jan 2010]
- ENST00000276218
- ENSP00000276218
- ENSG00000147262
- GPCR2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
ligand (chemical) | 0.93 | ||
tissue | 0.64 | ||
molecular function | 0.63 | ||
cell type or tissue | 0.61 | ||
biological term | 0.43 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 190.97 (req: < 5)
Gene RIFs: 15 (req: <= 3)
Antibodies: 234 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 190.97 (req: >= 5)
Gene RIFs: 15 (req: > 3)
Antibodies: 234 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 3
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 860
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 1